Technical Data Sheet

InVivoSIM anti-human PCSK9 (Bococizumab biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**SIM0096**
Clone:	**Bococizumab**
Isotype:	Human IgG2, κ
Recommended Isotype Control(s):	RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Immunogen:	Human PCSK9
Reported Applications:	*in vivo* functional assays *in vitro* functional assays ELISA Flow cytometry
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 μm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein A
Aggregation:	<5% Determined by SEC
RRID:	
Molecular Weight:	150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This Bococizumab biosimilar antibody uses the same variable regions as the therapeutic antibody Bococizumab, making it ideal for research use. Bococizumab is a humanized IgG2 monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a secreted serine protease that regulates plasma LDL cholesterol by controlling LDL receptor (LDLR) recycling. PCSK9 binds LDLR on hepatocytes and directs the receptor to lysosomal degradation, reducing LDLR surface expression and increasing circulating LDL cholesterol levels. By binding PCSK9 with high affinity, Bococizumab prevents its interaction with LDLR, thereby increasing receptor availability and enhancing LDL clearance.

Although therapeutic development of Bococizumab was discontinued due to immunogenicity and variable LDL-lowering responses, it remains a valuable research tool for studying PCSK9–LDLR biology, lipid metabolism, hepatocyte receptor regulation, and mechanisms underlying antibody-mediated PCSK9 inhibition. This Bococizumab biosimilar is well suited for investigating cardiovascular disease pathways, metabolic regulation, and therapeutic strategies targeting the PCSK9–LDLR axis.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/sim0096?bxcs=9k1b3a#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com